ORIGINAL RESEARCH article
Front. Mol. Neurosci.
Sec. Brain Disease Mechanisms
Volume 18 - 2025 | doi: 10.3389/fnmol.2025.1596021
This article is part of the Research TopicInnovative Approaches in Glioma Therapy: Exploring New Therapeutic FrontiersView all 9 articles
Clusterin Facilitates Glioma Progression via BCL2L1-Dependent Regulation of Apoptotic Resistance
Provisionally accepted
Qingqing Xu
Xin LiuYibo Zhang
Shiyu YuanWenli HuangMingshan PiQi XiongHongyan Zhou
Yuran Gui
Yifan XiaoXiaochuan Wang
Shu Xiji*
Yiyuan Xia*- School of Medicine, Jianghan University, Wuhan, Hebei Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Clusterin (CLU) is a multifunctional protein involved in various pathophysiological processes and diseases. Glioma, the most common aggressive primary brain tumor, is characterized by high morbidity, mortality, and extremely poor prognosis. Our research has found that CLU is upregulated in glioma and contributes to increased tumor malignancy. However, the specific regulatory mechanisms of CLU in the context of glioma are not fully understood.We used glioma public databases, immunohistochemistry (IHC), and immunoblotting techniques to evaluate the expression levels and prognostic value of CLU in glioma.Cell migration and proliferation assays, including the scratch wound healing and MTT assays, were conducted to assess the functional impact of CLU. In addition, immunoblotting and flow cytometry were used to analyze apoptosis-related proteins and CLU-BCL2L1 interactions. An in-situ tumor model using nude mice was established to investigate the effects of CLU in vivo.Bioinformatics analyses showed that both CLU and BCL2L1 were highly expressed in glioma, associated with poor clinical outcomes. Functional assays revealed that CLU and BCL2L1 promoted glioma cell migration and proliferation. Silencing CLU reduced the migration and proliferation of glioma cells, while overexpression of CLU enhanced these aggressive phenotypes. Mechanistic studies showed CLU regulated BCL2L1 expression, inhibiting apoptosis pathways and promoting malignancy. In vivo experiments confirmed the inhibitory effects of CLU downregulation on glioma growth.This study clarifies the role of the CLU-BCL2L1 axis in promoting glioma migration and proliferation both in vitro and in vivo. It suggests that targeting this pathway may be a promising therapeutic strategy for glioma.
Keywords: Glioma, clusterin (CLU), Migration, proliferation, Bcl2l1, Apoptosis
Received: 19 Mar 2025; Accepted: 26 May 2025.
Copyright: © 2025 Xu, Liu, Zhang, Yuan, Huang, Pi, Xiong, Zhou, Gui, Xiao, Wang, Xiji and Xia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Shu Xiji, School of Medicine, Jianghan University, Wuhan, Hebei Province, China
Yiyuan Xia, School of Medicine, Jianghan University, Wuhan, Hebei Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.